Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-month, muti-center, randomized, open-label, non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled everolimus with reduced cyclosporine versus 3.0g mycophenolate mofetil with standard dose cyclosporine in de novo heart transplant recipients.

Trial Profile

A 24-month, muti-center, randomized, open-label, non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled everolimus with reduced cyclosporine versus 3.0g mycophenolate mofetil with standard dose cyclosporine in de novo heart transplant recipients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate mofetil; Steroids
  • Indications Heart transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Sep 2015 Results presented at the 17th Congress of the European Society for Organ Transplantation
    • 16 Sep 2015 Results presented at the 17th Congress of the European Society for Organ Transplantation
    • 09 Sep 2013 Results presented at the 16th Congress of the European Society for Organ Transplantation.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top